{"paper_id":"72402832-f309-47b6-a0ec-80da7f37f204","body_text":"INTRODUCTION \nReview question / Objective: P: pelvic pain \nassociated with EMs; I: acupuncture; C: \nnon-penetrating needles; O: reduce the \npain level. \nCondition being studied: The usage of \nacupuncture for pelvic pain caused by \nendometriosis is common, although \nstudies have not been conducted to \nestablish its effectiveness. Hence, we will \nconduct a systematic review to assess the \nINPLASY 1\nInternational Platform of Registered Systematic Review and Meta-analysis Protocols\nINPLASY\nPROTOCOL\nEfficacy of Acupuncture for Pelvic \nPain associated with Endometriosis \nin Women: A protocol for systematic \nreview and meta-analysis\nXu, LX1; Sun, P2; Yan, DM3; Tu, B4.\nTo cite: Xu et al. Efficacy of \nAcupuncture for Pelvic Pain \nassociated with Endometriosis \nin Women: A protocol for \nsystematic review and meta-\nanalysis. Inplasy protocol \n202330006. doi: \n10.37766/inplasy2023.3.0006\nReceived: 03 March 2023\nPublished: 03 March 2023\nReview question / Objective: P: pelvic pain associated with \nEMs; I: acupuncture; C: non-penetrating needles; O: reduce \nthe pain level. \nCondition being studied: The usage of acupuncture for pelvic \npain caused by endometriosis is common, although studies \nhave not been conducted to establish its e ffectiveness. \nHence, we will conduct a systematic review to assess the \neffectiveness of acupuncture in treating endometriosis-\nrelated pelvicpain.  \nEligibility criteria: Study participants were eligible based on \nthe following criteria: 1) 18-45 years old; 2) following \nmenarche; 3) complete uterus and at least one ovary; 4) all \npatients had EMs \nINPLASY registration number: This protocol was registered with \nthe International Platform of Registered Systematic Review and \nMeta-Analysis Protocols (INPLASY) on 03 March 2023 and was \nlast updated on 03 March 2023 (registration number \nINPLASY202330006). \nCorresponding author: \nlingxia xu \nxulingxia94@163.com \nAuthor Affiliation:                  \nAcademician Workstation, \nJiangxi University of Chinese \nMedicine, Nanchang, Jiangxi, \nChina. \nSupport: Nos.2019XZZX-\nLG005. \nReview Stage at time of this \nsubmission: The review has \nnot yet started. \nConflicts of interest:          \nNone declared.\nXu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006\nXu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006 Downloaded from https://inplasy.com/inplasy-2023-3-0006/\n\neffectiveness of acupuncture in treating \nendometriosis-related pelvicpain. \nMETHODS \nSearch strategy: From the following seven \ndatabases, studies were extracted to \nFebruary 2023: PubMed, EMBASE, web of \nscience, Cochrane Library, China National \nKnowledge Infrastructure (CNKI), Wan \nFang Database (WanFang), sinomed and \nWeipu Database for Chinese Technical \nPeriodicals (VIP). We searched the \ninternational and Chinese clinical trial \nregistration platforms up to February 2023. \nP a r t i c i p a n t o r p o p u l a t i o n : S t u d y \nparticipants were eligible based on the \nfollowing criteria: 1) 18-45 years old; 2) \nfollowing menarche; 3) complete uterus \nand at least one ovary; 4) all patients had \nEMs. \nIntervention: Acupuncture. \nComparator: Non-penetrating needles. \nStudy designs to be included: RCTs. \nEligibility criteria: Study participants were \neligible based on the following criteria: 1) \n18-45 years old; 2) following menarche; 3) \ncomplete uterus and at least one ovary; 4) \nall patients had EMs. \nInformation sources: PubMed, EMBASE, \nweb of science, Cochrane Library, China \nNational Knowledge Infrastructure (CNKI), \nWan Fang Database (WanFang), sinomed \nand Weipu Database for Chinese Technical \nPeriodicals (VIP). \nMain outcome(s): Our study aimed to \ndetermine whether acupuncture can \nreduce the pain level (primary outcome), \nimprove different aspects of the quality of \nlife by Quality-of-life scales(he SF-36) and \nthe take-home-baby rate(secondary \noutcome) for patients with EMs. \nQuality assessment / Risk of bias analysis: \nAn assessment of bias risk was performed \nb y t w o i n v e s t i g a t o r s , w i t h a n y \ndisagreements being resolved by three \ninvestigators. Seven items were included in \nthis study, which were evaluated using the \nRoB 2 tool.random sequence generation; \nallocation concealment; blinding of \npatients and doctors; blinding of outcome \nassessment; incomplete and missing \noutcome data; selective outcome data \nreporting, other bias. \nStrategy of data synthesis: The continuous \ndata will be measured by Mean difference \nor Std Mean difference, 95% Confidence \ninterval and P values. The dichotomous \nvariables include will be estimated by \nRelative risk, 95% Confidence interval and \nP values. The chi-squared test and I2 \nstatistic will be used to test the statistical \nheterogeneity. \nSubgroup analysis: 1)by age: patients were \nstratified into two groups: mean age >35 \nyears and mean age≤35 years. 2)by the \nseverity of endometriosis: patients were \nstratified into three groups: I, II, or III \nendometriosis. \nSensitivity analysis: Sensitivity analysis will \nbe performed by excluding studies with \nhigh risk of bias and changing the \nstatistical model. \nCountry(ies) involved: China. \nOther relevant information: Endometriosis \n(EMs) is a chronic disease caused by active \nendometrial tissue (glands and stroma) \ngrowing outside the uterus.EMs is \ncharacterized primarily by pain, and 87.7% \nof patients experience dysmenorrhea, \n71.3% experience non-menstrual pain in \nthe abdomen, 57.4% experience total \nabdominal pain, 56.2% experience pain \nduring intercourse, 46.2% experience anal \npain, and 39.5% experience painful bowel \nmovement, which negatively in fluences \ntheir  mental and physical health, \nand  increases the social medical burde. \nModern medicine has a good analgesic and \nlesion inhibition effect, but pelvic pain is \nprone to relapses. \nKeywords: Acupuncture, Pelvic Pain, \nEndometriosis, systematic review, meta-\nanalysis. \nINPLASY 2Xu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006\nXu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006 Downloaded from https://inplasy.com/inplasy-2023-3-0006/\n\nContributions of each author: \nAuthor 1 - LINGXIA XU. \nEmail: xulingxia94@163.com \nAuthor 2 - PENG SUN. \nEmail: xlx1992a@126.com \nAuthor 3 - dongmei yan. \nEmail: yandongmei2021@outlook.com \nAuthor 4 - qing tu. \nEmail: 2720477121@qq.com \nAuthor 5 - bin li. \nEmail: bin2021li@outlook.com \nINPLASY 3Xu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006\nXu et al. Inplasy protocol 202330006. doi:10.37766/inplasy2023.3.0006 Downloaded from https://inplasy.com/inplasy-2023-3-0006/","source_license":"CC0","license_restricted":false}